Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Both Alzheimer's disease and senile dementia of the Alzheimer type (AD/SDAT) are progressive dementias characterized neuropathologically by the presence in the cerebral cortex of numerous neurofibrillary tangles and neuritic plaques. We use the abbreviation AD/SDAT to denote all such cases, irrespective of age of onset. Studies of neurotransmitter-related parameters in autopsied brain tissues from patients with AD/SDAT have, to date, been confined to five putative transmitter systems. Acetycholine-releasing neurones seem to be most markedly and consistently affected, as judged by the extensive reductions in choline acetyltransferase (ChAT) and acetylcholinesterase activities that have been reported. Despite numerous studies, there is no consistent evidence for the involvement of neurones releasing dopamine, noradrenaline, serotonin, or gamma-aminobutyric acid in AD/SDAT, nor for loss of muscarinic cholinergic receptors. Thus, the involvement of cholinergic neurones in AD/SDAT seems to be specific. However, the possible involvement of neurones using other chemicals as transmitters has yet to be explored. The recent recognition of the existence of so-called 'peptidergic neurones' in the mammalian brain (for review see ref. 8) and the availability of radioimmunoassay (RIA) techniques for studying these peptides, have led us to begin a systematic investigation of neuropeptides in autopsied brain tissue from cases of AD/SDAT, and from neurologically normal individuals. We report here results obtained with a RIA for somatostatin, showing that somatostatin-like immunoreactivity in the cerebral cortex is reduced in tissue from AD/SDAT patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ not only affects intracellular vesicular trafficking but could also affect primary cilia function directly or indirectly via its cognate binding receptors such as LRP1 [15, 50, 75].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“In addition, SST administration has been shown to be effective in improving cognitive impairment in AD patients [12, 15].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Dysfunctional SOMs have been identified as a hallmark of AD, and loss of SOMs in the cortex is associated with AD pathologies [10, 15, 65].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Additionally, AD patients have a specific loss of somatostatin-positive interneurons in the cortex [94] and hippocampus [95].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [94]
Citations
Cites
Hökfelt, T., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,547
NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
Neurotransmitter-related enzymes in senile dementia of the alzheimer type
Davies, P. (1979) · Brain Research · doi:10.1016/0006-8993(79)90336-6 · Cited by 634
Self-citationThe Prevalence and Malignancy of Alzheimer Disease: A Major Killer
Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040001001 · Cited by 619
Self-citationDementia of the Alzheimer Type
Terry, R. D., & Davies, P. (1980) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.03.030180.000453 · Cited by 529
Self-citationPrevalence and Malignancy of Alzheimer Disease
Lijtmaer, H., Fuld, P. A., & Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040088017 · Cited by 517
Self-citationNEOCORTICAL CHOLINERGIC NEURONS IN ELDERLY PEOPLE
White, P., Goodhardt, M. J., Keet, J. P., Hiley, C. R., Carrasco, L. H., Williams, I. E. I., & Bowen, D. M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92114-6 · Cited by 489
Davies, P., & Verth, A. H. (1977) · Brain Research · doi:10.1016/0006-8993(77)90758-2 · Cited by 313
Self-citationRadioimmunoassay for GH-Release Inhibiting Hormone
Arimura, A., Sato, H., Coy, D. H., & Schally, A. V. (1975) · Experimental Biology and Medicine · doi:10.3181/00379727-148-38631 · Cited by 302
Research works printed but not linked: 1
- Wisniewski, H. M. & Terry, R. D. in Neurobiology of Aging (eds Terry, R. D. & Gershon, S.) 265–280 (Raven, New York, 1976).
Cited by
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation
Coyle, J. T., Price, D. L., & DeLong, M. R. (1983) · Science · doi:10.1126/science.6338589 · Cited by 3,052
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Oxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., Renbing, X., & Peck, A. (1988) · Annals of Neurology · doi:10.1002/ana.410230206 · Cited by 1,225
Self-citationApolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases
Huang, Y., & Mahley, R. W. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.025 · Cited by 829
Katzman, R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604103141506 · Cited by 801
Self-citationSome morphometric aspects of the brain in senile dementia of the alzheimer type
Terry, R. D., Peck, A., DeTeresa, R., Schechter, R., & Horoupian, D. S. (1981) · Annals of Neurology · doi:10.1002/ana.410100209 · Cited by 801
Self-citationThe Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives
Wanka, L., Iqbal, K., & Schreiner, P. R. (2013) · Chemical Reviews · doi:10.1021/cr100264t · Cited by 696
Pathology of Parkinson’s disease: Changes other than the nigrostriatal pathway
Jellinger, K. A. (1991) · Molecular and Chemical Neuropathology · doi:10.1007/bf03159935 · Cited by 684
Appel, S. H. (1981) · Annals of Neurology · doi:10.1002/ana.410100602 · Cited by 698
Johansson, O., Hökfelt, T., & Elde, R. P. (1984) · Neuroscience · doi:10.1016/0306-4522(84)90233-1 · Cited by 674
Perforant pathway changes and the memory impairment of Alzheimer's disease
Hyman, B. T., Van Hoesen, G. W., Kromer, L. J., & Damasio, A. R. (1986) · Annals of Neurology · doi:10.1002/ana.410200406 · Cited by 672
Davies, C. A., Mann, D. M. A., Sumpter, P. Q., & Yates, P. O. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90057-8 · Cited by 628
Cholinergic function and intellectual decline in Alzheimer's disease
Collerton, D. (1986) · Neuroscience · doi:10.1016/0306-4522(86)90002-3 · Cited by 601
Reichlin, S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312223092506 · Cited by 577
Lewis, D., Campbell, M., Terry, R., & Morrison, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-06-01799.1987 · Cited by 578
“The prosomatostatin-derived peptide (PSDP) system of the cortex is profoundly altered in AD, as reflected in decreased tissue levels of PSDP (Davies et al., 1980; Rossor et al., 1980), the presence of PSDP-immunoreactive profiles in NP (Armstrong et al., 1985; Morrison et al., 1985) and a reduction in PSDP receptor nu…”
BackgroundInfluentialSelf-citationNeurotransmitters in the regulation of neuronal cytoarchitecture
Mattson, M. P. (1988) · Brain Research Reviews · doi:10.1016/0165-0173(88)90020-3 · Cited by 520
Oliva, A. A., Jiang, M., Lam, T., Smith, K. L., & Swann, J. W. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-09-03354.2000 · Cited by 498
“…bars: a, c, j, 100 mm; d–g, 50 mm. 1987, Sloviter and Lowenstein, 1992), traumatic brain injury (Lowenstein et al., 1992), and Alzheimer’s disease (Davies et al., 1980; Roberts et al., 1985; Bissette, 1997; Grouselle et al., 1998; Van Uden et al., 1999), disorders in which SOM-expressing…”
BackgroundMathys, H., Peng, Z., Boix, C. A., Victor, M. B., Leary, N., Babu, S., Abdelhady, G., Jiang, X., Ng, A. P., Ghafari, K., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.039 · Cited by 495
“63 Going beyond the subclass level of inhibitory neurons, we identified a subset of three vulnerable somato-statin inhibitory neuron subtypes with transcriptomically similar identities that were significantly depleted in AD.”
BackgroundSomatostatin in the central nervous system: Physiology and pathological modifications
Epelbaum, J. (1986) · Progress in Neurobiology · doi:10.1016/0301-0082(86)90012-2 · Cited by 466
Quantitative assessment of cortical synaptic density in Alzheimer's disease
Scheff, S. W., DeKosky, S. T., & Price, D. A. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90059-9 · Cited by 446
The neuropharmacological and neurochemical basis of place learning in the Morris water maze
McNamara, R. K., & Skelton, R. W. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90006-l · Cited by 430
Neurochemical characteristics of early and late onset types of Alzheimer's disease.
Rossor, M. N., Iversen, L. L., Reynolds, G. P., Mountjoy, C. Q., & Roth, M. (1984) · BMJ · doi:10.1136/bmj.288.6422.961 · Cited by 417
The Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions
BARTUS, R. T., DEAN, R. L., PONTECORVO, M. J., & FLICKER, C. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb37600.x · Cited by 383
Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation
Saito, T., Iwata, N., Tsubuki, S., Takaki, Y., Takano, J., Huang, S.-M., Suemoto, T., Higuchi, M., & Saido, T. C. (2005) · Nature Medicine · doi:10.1038/nm1206 · Cited by 361
“A prominent decrease in this neuropeptide also represents a pathological characteristic of Alzheimer diseas”
BackgroundKowall, N. W., & Kosik, K. S. (1987) · Annals of Neurology · doi:10.1002/ana.410220514 · Cited by 351
Savonenko, A., Xu, G. M., Melnikova, T., Morton, J. L., Gonzales, V., Wong, M. P. F., Price, D. L., Tang, F., Markowska, A. L., & Borchelt, D. R. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.10.022 · Cited by 346
Animal models of Alzheimer's disease: experimental cholinergic denervation
Smith, G. (1988) · Brain Research Reviews · doi:10.1016/0165-0173(88)90016-1 · Cited by 337
Glutamate dysfunction in Alzheimer's disease: an hypothesis
Maragos, W. F., Greenamyre, J. T., Penney, J. B., & Young, A. B. (1987) · Trends in Neurosciences · doi:10.1016/0166-2236(87)90025-7 · Cited by 334
Transmitter deficits in Alzheimer's disease
Hardy, J., Adolfsson, R., Alafuzoff, I., Bucht, G., Marcusson, J., Nyberg, P., Perdahl, E., Wester, P., & Winblad, B. (1985) · Neurochemistry International · doi:10.1016/0197-0186(85)90050-6 · Cited by 328
Andrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., Yoon, S. Y., Zwilling, D., Yan, T. X., Chen, L., & Huang, Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4040-10.2010 · Cited by 326
“There is evidence of GABAergic interneuron impairment in Alzheimer’s disease patients, including a decrease in GABA or somatostatin levels in the brain and CSF (Davies et al., 1980; Bareggi et al., Received Aug. 3, 2010; revised Aug. 23, 2010; accepted Aug. 26, 2010.”
BackgroundAubert, I., Araujo, D. M., Cécyre, D., Robitaille, Y., Gauthier, S., & Quirion, R. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09752.x · Cited by 320
Enhancement of Memory in Alzheimer Disease With Insulin and Somatostatin, but Not Glucose
Craft, S., Asthana, S., Newcomer, J. W., Wilkinson, C. W., Matos, I. T., Baker, L. D., Cherrier, M., Lofgreen, C., Latendresse, S., Petrova, A., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1135 · Cited by 312
Biochemical changes in Dementia disorders of Alzheimer type (AD/SDAT)
Gottfries, C.-G., Adolfsson, R., Aquilonius, S.-M., Carlsson, A., Eckernas, S.-A., Nordberg, A., Oreland, L., Svennerholm, L., Wiberg, Å., & Winblad, B. (1983) · Neurobiology of Aging · doi:10.1016/0197-4580(83)90002-7 · Cited by 304
Murray, C. L., & Fibiger, H. C. (1985) · Neuroscience · doi:10.1016/0306-4522(85)90273-8 · Cited by 299
Molecular cloning and functional expression of a brain-specific somatostatin receptor.
Bruno, J. F., Xu, Y., Song, J., & Berelowitz, M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.23.11151 · Cited by 294
Freund, T. F., & Meskenaite, V (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.2.738 · Cited by 292
The role of G protein-coupled receptors in the pathology of Alzheimer's disease
Thathiah, A., & De Strooper, B. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2977 · Cited by 288
Rossor, M. N. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91212-0 · Cited by 283
Alzheimer’s disease brain-derived extracellular vesicles spread tau pathology in interneurons
Ruan, Z., Pathak, D., Venkatesan Kalavai, S., Yoshii-Kitahara, A., Muraoka, S., Bhatt, N., Takamatsu-Yukawa, K., Hu, J., Wang, Y., Hersh, S., et al. (2021) · Brain · doi:10.1093/brain/awaa376 · Cited by 283
“Alzheimer’s disease patients showed loss of specific somatostatin interneurons in the hippocampus and cortex (Davies et al., 1980; Chan-Palay, 1987).”
BackgroundDementia in idiopathic Parkinson's disease: A neuropathological study of 32 cases
Gaspar, P., & Gray, F. (1984) · Acta Neuropathologica · doi:10.1007/bf00695605 · Cited by 275
Marino, M. J., Rouse, S. T., Levey, A. I., Potter, L. T., & Conn, P. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11465 · Cited by 275
Davies, P., & Terry, R. D. (1981) · Neurobiology of Aging · doi:10.1016/0197-4580(81)90053-1 · Cited by 274
Self-citationMemory: Anatomical Organization of Candidate Brain Regions
Amaral, D. G. (1987) · Comprehensive Physiology · doi:10.1002/cphy.cp010507 · Cited by 259
Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients
Morrison, J. H., Rogers, J., Scherr, S., Benoit, R., & Bloom, F. E. (1985) · Nature · doi:10.1038/314090a0 · Cited by 264
Individual differences in aging: Behavioral and neurobiological correlates
Markowska, A. L., Stone, W. S., Ingram, D. K., Reynolds, J., Gold, P. E., Conti, L. H., Pontecorvo, M. J., Wenk, G. L., & Olton, D. S. (1989) · Neurobiology of Aging · doi:10.1016/s0197-4580(89)80008-9 · Cited by 252
De Souza, E. B., Whitehouse, P. J., Kuhar, M. J., Price, D. L., & Vale, W. W. (1986) · Nature · doi:10.1038/319593a0 · Cited by 255
Chan‐Palay, V. (1987) · Journal of Comparative Neurology · doi:10.1002/cne.902600205 · Cited by 254
The role of cortical connectivity in Alzheimer's disease pathogenesis: A review and model system
de LaCoste, M.-C., & White, C. L. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90015-4 · Cited by 253
Cellular biology of somatostatin receptors
Csaba, Z., & Dournaud, P. (2001) · Neuropeptides · doi:10.1054/npep.2001.0848 · Cited by 250
Reduced Numbers of Somatostatin Receptors in the Cerebral Cortex in Alzheimer's Disease
Beal, M. F., Mazurek, M. F., Tran, V. T., Chattha, G., Bird, E. D., & Martin, J. B. (1985) · Science · doi:10.1126/science.2861661 · Cited by 251
The neurobiologie consequences of down syndrome
Coyle, J. T., Oster-Granite, M. L., & Gearhart, J. D. (1986) · Brain Research Bulletin · doi:10.1016/0361-9230(86)90074-2 · Cited by 248
Aminergic systems in Alzheimer's disease and Parkinson's disease
D'Amato, R. J., Zweig, R. M., Whitehouse, P. J., Wenk, G. L., Singer, H. S., Mayeux, R., Price, D. L., & Snyder, S. H. (1987) · Annals of Neurology · doi:10.1002/ana.410220207 · Cited by 248
Regional changes in brain glucose metabolism reflect cognitive impairments in aged rats
Gage, F., Kelly, P., & Bjorklund, A. (1984) · The Journal of Neuroscience · doi:10.1523/jneurosci.04-11-02856.1984 · Cited by 243
“However, there is substantial evidence that the development of dementia is correlated with specific neuropathological processes that are either different from or at least much more extensive than in normal aging (Ingvar et al., 1977; Perry et al., 1978; Davis et al., 1980; Whitehouse et al., 1982).”
BackgroundDecreased levels of protein kinase C in Alzheimer brain
Cole, G., Dobkins, K. R., Hansen, L. A., Terry, R. D., & Saitoh, T. (1988) · Brain Research · doi:10.1016/0006-8993(88)90021-2 · Cited by 239
Self-citationOral physostigmine treatment of patients with Alzheimer's disease
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.1.28 · Cited by 240
Prévot, T., & Sibille, E. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0727-3 · Cited by 231
Neurotransmitter changes in alzheimer's disease: Implications to diagnostics and therapy
Reinikainen, K. J., Soininen, H., & Riekkinen, P. J. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490270419 · Cited by 229
Kowall, N. W., & Beal, M. F. (1988) · Annals of Neurology · doi:10.1002/ana.410230202 · Cited by 230
Bossers, K., Wirz, K. T. S., Meerhoff, G. F., Essing, A. H. W., van Dongen, J. W., Houba, P., Kruse, C. G., Verhaagen, J., & Swaab, D. F. (2010) · Brain · doi:10.1093/brain/awq258 · Cited by 230
Ramos, B., Baglietto-Vargas, D., Rio, J. C. D., Moreno-Gonzalez, I., Santa-Maria, C., Jimenez, S., Caballero, C., Lopez-Tellez, J. F., Khan, Z. U., Ruano, D., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.022 · Cited by 216
A selective loss of somatostatin in the hippocampus of patients with temporal lobe epilepsy
Robbins, R. J., Brines, M. L., Kim, J. H., Adrian, T., De Lanerolle, N., Welsh, S., & Spencer, D. D. (1991) · Annals of Neurology · doi:10.1002/ana.410290316 · Cited by 216
Alzheimer's disease: Glutamate depletion in the hippocampal perforant pathway zone
Hyman, B. T., Van Hoesen, G. W., & Damasio, A. R. (1987) · Annals of Neurology · doi:10.1002/ana.410220110 · Cited by 219
Metabolism of amyloid-β peptide and Alzheimer's disease
Iwata, N., Higuchi, M., & Saido, T. C. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.03.010 · Cited by 220
Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes
Perry, E. K., Blessed, G., Tomlinson, B. E., Perry, R. H., Crow, T. J., Cross, A. J., Dockray, G. J., Dimaline, R., & Arregui, A. (1981) · Neurobiology of Aging · doi:10.1016/0197-4580(81)90032-4 · Cited by 212
Somatostatin Augments the M-Current in Hippocampal Neurons
Moore, S. D., Madamba, S. G., Joëls, M., & Siggins, G. R. (1988) · Science · doi:10.1126/science.2892268 · Cited by 214
The Cholinergic Hypothesis of Memory: A Review of Animal Experiments
Hagan, J. J., & Morris, R. G. M. (1988) · Handbook of Psychopharmacology · doi:10.1007/978-1-4613-0933-8_7 · Cited by 210
Eckman, C. B., & Eckman, E. A. (2005) · Biochemical Society Transactions · doi:10.1042/bst20051101 · Cited by 200
Atack, J. R., Perry, E. K., Bonham, J. R., Perry, R. H., Tomlinson, B. E., Blessed, G., & Fairbairn, A. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90302-6 · Cited by 210
Weiss, J. H., Koh, J.-Y., & Choi, D. W. (1989) · Brain Research · doi:10.1016/0006-8993(89)90970-0 · Cited by 208
β-Amyloid and the Pathogenesis of Alzheimer's Disease
Flier, J. S., Underhill, L. H., Yankner, B. A., & Mesulam, M.-M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112263252605 · Cited by 207
Chronwall, B. M., Chase, T. N., & O'Donohue, T. L. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90164-2 · Cited by 203
Emerging roles of pathogens in Alzheimer disease
Miklossy, J. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002006 · Cited by 201
“Alterations of various neurotransmitters, neuropeptides and hormones are reported to occur in AD (Refs 65, 66, 67, 68).”
BackgroundGABAergic Inhibitory Interneuron Deficits in Alzheimer’s Disease: Implications for Treatment
Xu, Y., Zhao, M., Han, Y., & Zhang, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00660 · Cited by 203
“There are significantly fewer SST neurons in the frontal and temporal lobes of AD patients as measured by high-performance liquid chromatography analysis or immunohistochemical staining (Davies et al., 1980; Davies and Terry, 1981; Beal et al., 1985, 1986; Candy et al., 1985).”
BackgroundMemory deficits in Alzheimer's patients: A comprehensive review
Carlesimo, G. A., & Oscar-Berman, M. (1992) · Neuropsychology Review · doi:10.1007/bf01108841 · Cited by 183
Dringenberg, H. C. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00261-8 · Cited by 191
Craft, S., Dagogo-Jack, S. E., Wiethop, B. V., Murphy, C., Nevins, R. T., Fleischman, S., Rice, V., Newcomer, J. W., & Cryer, P. E. (1993) · Behavioral Neuroscience · doi:10.1037/0735-7044.107.6.926 · Cited by 191
Senile plaques in cortex of aged normal monkeys
Struble, R. G., Price, D. L., Cork, L. C., & Price, D. L. (1985) · Brain Research · doi:10.1016/0006-8993(85)91298-3 · Cited by 189
Baraban, S. C., & Tallent, M. K. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.01.008 · Cited by 187
Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model
Molchan, S. E., Martinez, R. A., Hill, J. L., Weingartner, H. J., Thompson, K., Vitiello, B., & Sunderland, T. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90017-g · Cited by 187
Somatostatin-Expressing Inhibitory Interneurons in Cortical Circuits
Yavorska, I., & Wehr, M. (2016) · Frontiers in Neural Circuits · doi:10.3389/fncir.2016.00076 · Cited by 185
“SOM levels are also reduced in the brains of Alzheimer’s disease patients examined postmortem, specifically in cortical layers 3 and 5 (Davies et al., 1980; Vécsei and Klivenyi, 1995).”
BackgroundAutoradiographic mapping of somatostatin receptors in the rat central nervous system and pituitary
Reubi, J. C., & Maurer, R. (1985) · Neuroscience · doi:10.1016/0306-4522(85)90261-1 · Cited by 184
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
Najm, R., Jones, E. A., & Huang, Y. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0324-6 · Cited by 183
Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support
Marsh, S. E., & Blurton-Jones, M. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.02.006 · Cited by 181
“…that exhibit more widespread pathology and loss of varying neuronal subtypes in multiple brain regions, such as AD, this kind of neuronal replacement paradigm becomes evenmore challenging (Davies and Maloney, 1976; Davies et al., 1980; Hardy et al., 1987; Hyman et al., 1987; Lowe et al., 1990).”
Ophthalmologic manifestations of Alzheimer's disease
Katz, B., & Rimmer, S. (1989) · Survey of Ophthalmology · doi:10.1016/0039-6257(89)90127-6 · Cited by 181
Selenium and Alzheimer's Disease: A Systematic Review
Loef, M., Schrauzer, G. N., & Walach, H. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110414 · Cited by 181
Agrin and microvascular damage in Alzheimer’s disease
Berzin, T. M., Zipser, B. D., Rafii, M. S., Kuo—Leblanc, V., Yancopouloš, G. D., Glass, D. J., Fallon, J. R., & Stopa, E. G. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00121-4 · Cited by 179
Tuszynski, M. H., Sang U, H., Yoshida, K., & Gage, F. H. (1991) · Annals of Neurology · doi:10.1002/ana.410300502 · Cited by 183
Mitochondrial function in brain tissue in primary degenerative dementia
Sims, N. R., Finegan, J. M., Blass, J. P., Bowen, D. M., & Neary, D. (1987) · Brain Research · doi:10.1016/0006-8993(87)91553-8 · Cited by 182
Reduced lumbar CSF somatostatin in levels in Alzheimer's disease
Wood, P. L., Etienne, P., Lal, S., Gauthier, S., Cajal, S., & Nair, N. P. V. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90099-6 · Cited by 181
Alzheimer‐related neuronal protein A68: Specificity and distribution
Wolozin, B., & Davies, P. (1987) · Annals of Neurology · doi:10.1002/ana.410220412 · Cited by 177
Self-citationAlz‐50 Antibody recognizes alzheimer‐related neuronal changes
Hyman, B. T., Van Hoesen, G. W., Wolozin, B. L., Davies, P., Kromer, L. J., & Damasio, A. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230410 · Cited by 176
Self-citationBakst, I., Avendano, C., Morrison, J., & Amaral, D. (1986) · The Journal of Neuroscience · doi:10.1523/jneurosci.06-05-01452.1986 · Cited by 176
“Finally, the loss of cortical and hippocampal somatostatin has been correlated with the pathology of Alzheimer’s disease (Davies and Terry, 1981; Davies et al., 1980; Rossor et al., 1980).”
BackgroundMultiscale causal networks identify VGF as a key regulator of Alzheimer’s disease
Beckmann, N. D., Lin, W.-J., Wang, M., Cohain, A. T., Charney, A. W., Wang, P., Ma, W., Wang, Y.-C., Jiang, C., Audrain, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17405-z · Cited by 172
Grimm, M. O. W., Mett, J., Stahlmann, C. P., Haupenthal, V. J., Zimmer, V. C., & Hartmann, T. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00098 · Cited by 159
Neuropeptides in learning and memory
Borbély, É., Scheich, B., & Helyes, Z. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.10.012 · Cited by 166
“Lower levels of somatostatin in the cerebral cortex and cerebrospinal fluid is a typical feature of AD patients (Davies et al., 1980), and somatostatin is also a key regulator of neprilysin (degrading enzyme of Ab) activity (Saito et al.”
BackgroundHellström-Lindahl, E., Ravid, R., & Nordberg, A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.10.010 · Cited by 165
Long-Term Neuropathological and Neurochemical Effects of Nucleus Basalis Lesions in the Rat
Arendash, G. W., Millard, W. J., Dunn, A. J., & Meyer, E. M. (1987) · Science · doi:10.1126/science.2890210 · Cited by 168
Metadata
- Authors
- Davies, P., Katzman, R., & Terry, R. D.
- Affiliations
- Albert Einstein College of Medicine (US)
- Venue
- Nature
- Published
- 1980-11
- Volume
- 288
- Issue
- 5788
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034969383
- Cited by
- 882
- References
- 9
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 20 · 2023: 18 · 2022: 11 · 2021: 11 · 2020: 19 · 2019: 8 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 9 · 2012: 8
- FWCI
- 25.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- Alzheimer's disease, senile dementia of the Alzheimer type, somatostatin, somatostatin-like immunoreactivity, cerebral cortex, neuropeptides, peptidergic neurons, neurotransmitter systems, cholinergic neurons, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Alzheimer Disease, Cerebral Cortex, Choline O-Acetyltransferase, Dementia, Humans, Middle Aged, Radioimmunoassay, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.